Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

Bristol Myers Squibb seeks Independent Research applications across all therapeutic areas.  Our Areas of Interest outline additional criteria to help guide the scientific community.  All concept applications submitted that best align with our interests will be considered and evaluated. 

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Hematology 28-May-21 21-Jun-21 23-July-21
Immunology – (ozanimod) Multiple Sclerosis 26-Mar-21 3-May-21 21-May-21
Immunology – (ozanimod) Ulcerative colitis 31-May-21 31-May-21 23-Jul-21
Oncology 1-Mar-21 29-Mar-21 23-Apr-21
Immunology – TYK2 (deucravacitinib) 8-Mar-21 12-Apr-21 14-May-21
Cardiovascular – (mavacamten) Hypertrophic Cardiomyopathy 10-May-21 14-Jun-21 9-Jul-21

 


Myeloid - Oral Azacitidine (CC-486) ISR Areas of Interest – 2021 RFP Cycle 2

 

In scope:

  • Efficacy and safety of Oral Azacitidine (CC-486) alone and in combination in various myeloid malignancies

Out of scope:

  • None

Myeloid - Luspatercept ISR Areas of Interest - 2021 RFP Cycle 2

In scope:

  • Evaluation of epidemiology, disease burden, and treatment patterns by country and region for B-thal
  • Luspatercept alone and in combination with other therapies in MDS and B-thal
  • Luspatercept use in anemias other than MDS and B-thal related anemia

Out of scope:

  • ESA treatment rescue post luspatercept failure 
  • Luspatercept 1L monotherapy in del5q MDS pts

Myeloid - Fedratinib ISR Areas of Interest - 2021 RFP Cycle 2

 

In scope:

  • Use of fedratinib in other disease areas outside MF
  • Efficacy and safety of fedratinib alone and in combination for MF, including subpopulations of patients with high unmet need

Out of scope:

  • Fedratinib use in AML, essential thrombocythemia, MDS, ALL

Lymphoma - Iberdomide ISR Areas of Interest - 2021 RFP Cycle 2

 

In scope:

  • Efficacy and safety of iberdomide-based therapies in R/R NHL
  • Efficacy and safety of iberdomide-based therapies in first line FL and DLBCL in selected populations of patients (with selection rationale) 
  • Impact of iberdomide-based therapies on QoL and patient reported outcomes in R/R FL and R/R DLBCL

Out of scope:

  • Iberdomide + R-CHOP in 1L DLBCL
  • Iberdomide + Tafasitamab in R/R DLBCL
  • Iberdomide + Bendamustine + Rituxan in R/R DLBCL
  • Iberdomide + PI3K inhibitors in R/R NHL

Multiple Myeloma - Iberdomide ISR Areas of Interest - 2021 RFP Cycle 2

 

In scope:

  • Efficacy and safety of Iberdomide-based therapies in NDMM, in both the transplant-eligible and –ineligible settings
  • Efficacy and safety of Iberdomide-based therapies in RRMM at first or second relapse
  • Efficacy and safety of Iberdomide-based therapies in combination with and/or as maintenance following cellular and immune-based therapies, including CAR T and T-cell engagers
  • Impact of Iberdomide on patient reported outcomes and QOL assessments

Out of scope:

  • Combination with melphalan

Multiple Myeloma - CC-92480 ISR Areas of Interest - 2021 RFP Cycle 2

 

In scope:

  • Safety and Efficacy of CC-92480 in combination with novel and existing agents in RRMM, including MAbs, ADCs, and small molecules 
  • Safety and efficacy of CC-92480-based combinations in patients relapsing following cellular, immune, and CELMoD-based therapies, including Iberdomide, CAR T and T-cell engagers
  • Safety and efficacy of CC-92480-based combinations in patients with high-risk disease features in RRMM
  • Impact of CC-92480 on patient reported outcomes and QOL assessments

Out of scope:

  • CC-92480 in NDMM
  • CC-92480 in combination with melphalan

Multiple Myeloma - Elotuzumab ISR Areas of Interest - 2021 RFP Cycle 2

 

In scope:

  • Efficacy and safety of elotuzumab in combination with CELMoD compounds in patients with RRMM
  • Efficacy and safety of elotuzumab in combination with CELMoD compounds following BCMA-targeted therapies

Out of scope:

  • None

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here
  • If you are a potential investigator who is interested in seeking support for independent research involving NKTR-214 (Bempegaldesleukin) & Nivolumab, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application